Rapid responses are electronic letters to the editor. They enable our users to debate issues raised in articles published on thebmj.com. Although a selection of rapid responses will be included online and in print as readers' letters, their first appearance online means that they are published articles. If you need the url (web address) of an individual response, perhaps for citation purposes, simply click on the response headline and copy the url from the browser window. Letters are indexed in PubMed.
Camm and Savalieva  provide a clear, concise and practical
description of the
"pill-in-the-pocket" approach to the treatment of paroxysmal atrial
(AF). Anticoagulation therapy is recommended for patients at high risk of
thromboembolism based on the CHADS 2 risk scoring system. However, the 'A'
in the CHADS 2 acronym, as initially described by Gage et al  referred
'Age>75 years', and not 'Angina' as indicated. Finally, it is worth
noting that the
CHADS 2 scheme should not be applied to patients with AF at high risk of
thromboembolism (eg: patients with mitral stenosis).
1. Camm JA, Savalieva I. Some patients with paroxysmal atrial
carry flecainide or propafenone to self treat. BMJ 2007; 334: 637.
2. Gage BF, Waterman AD, Shannon W et al. Validation of clinical
schemes for predicting stroke. Results from the National Registry of
Fibrillation. JAMA 2001; 285: 2864-70.